Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalviso System performance in postoperative pain
NCT02662764Phase 3Completed
- Sponsor
- Talphera
- Start
- Sep 2016
- Primary completion
- Apr 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of SurBred in postoperative pain, sponsored by Talphera. Primary endpoints: Percentage of Patients Who Experienced at Least One System-generated Error at 72 hours, Percentage of Patients Who Experienced Either a System-generated Error or a Misplaced Tablet at 72 hours and 5 more. Started Sep 2016; status: completed.
02
Drugs
SurBred
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02662764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662764.